Trial Profile
Evaluation of ZD1839 [gefitinib] (NSC 715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 01 Dec 2007 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2005 New trial record.